Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

Pfizer maternal RSV vaccine approved

4
SHARES

The US Food and Drug Administration (FDA) has authorised an RSV vaccine for pregnant individuals, which in one study, reduced the risk of severe LRTD by 81.8 percent within 90 days after birth.

Pfizer maternal RSV vaccine approved by FDA

Abrysvo is approved for pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants. The US Food and Drug Administration (FDA)-approved treatment, is the first RSV vaccine indicated for infants from birth to six months of age. It is approved for use at 32 through to 36 weeks pregnancy gestation. US FDA granted approval of Abrysvo to Pfizer Inc.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

This news follows similar regulatory action by the US FDA in recent months. In July 2023, the US government body approved the only monoclonal antibody for protection of infants in their first RSV season.

First RSV vaccine approved for older adults

Abrysvo’s approval “marks a significant milestone” Annaliesa Anderson, PhD, Senior Vice President and Chief Scientific Officer of Vaccine Research and Development at Pfizer stated. At present, Pfizer is the only company with an RSV vaccine to help protect older adults, in addition to help immunise infants through maternal immunisation, the company declared.

“RSV is a common cause of illness in children, and infants are among those at highest risk for severe disease, which can lead to hospitalisation,” explained Dr Peter Marks, PhD, Director of the FDA’s Center for Biologics Evaluation and Research.

Clinical evidence for the RSV vaccine

A Phase III clinical study evaluated approximately 3,500 pregnant individuals who were given Abrysvo, compared to the same number received a placebo. The bivalent RSV prefusion F (RSVpreF) RSV vaccine reduced the risk of severe LRTD by 81.8 percent within 90 days after birth. Within 180 days after birth, the risk rate was 69.4 percent. The results of the MATISSE study were published in the NEMJ in April 2023.

In a subgroup of participants who were between 32 through to 36 weeks gestation, approximately 1,500 received Abrysvo and 1,500 received placebo. Abrysvo was found to reduce the risk of LRTD by 34.7 percent. It reduced the risk of severe LRTD by 91.1 percent within 90 days after birth when compared to placebo. Within 180 days after birth, Abrysvo reduced the risk of LRTD by 57.3 percent and by 76.5 percent for severe LRTD, compared to placebo.

Two studies investigated the safety of the RSV vaccine Abrysvo. The first study had approximately 3,600 participants in each cohort. The second study evaluated approximately 100 pregnant individuals in each group. Data indicated a potential risk of hypertensive disorders of pregnancy, including pre-eclampsia. Therefore, postmarketing studies are required by the FDA to assess the signal of serious risk for these conditions.

Share via
Share via